The global market for Intravenous Immunoglobulin (IVIg) market is growing continuously and expected to grow at a CAGR of 5.9% from 2016 to 2023. The global Intravenous Immunoglobulin (IVIg) market has been evaluated as moderately growing market and it is expected that the market will continue to grow similarly in the near future. The demand for new products and therapy is growing continuously. The market for Intravenous Immunoglobulin (IVIg) was around US$ 5910.8 million in 2016 and is expected to grow at a CAGR of 5.9% by 2023.
Major Players in Intravenous Immunoglobulin (IVIg) market:
- ABEONA THERAPEUTICS (US),
- Baxter (US),
- BDI Pharma (US),
- Biotest AG.(Germany),,
- China Biologic Products, Inc. (China),
- CSL Behring (US),
- Grifols Inc. (Spain),
- Kedrion S.p.A (us),
- Octapharma (Switzerland),
- Shire (Republic of Ireland),
Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/3137
Biotest AG. Was found in 1946 and based in Germany. Biotest AG is one of the key players in the market. This company employed about 2,527 people throughout the world and total revenue of the company is US$ 622.7million in 2016. In May 2017, Biotest AG sold their US therapy business to ADMA Biologics, Inc. and received specified current products and a rights related to first order for distribution of upcoming products of ADMA Biologics, Inc. in Europe and selected parts of Asia and middle East.
Octapharma was founded in 1983. Octapharma is Switzerland based one of the largest human protein product manufacture in the world. This company is in development and production of human proteins for human plasma and human cell line. The total revenue of the company in 2016 was US$ 1.8 billion. Company has more than 7,000 employees throughout the globe. In 2016, Octopharma Plasma, Inc.’s Testing Laboratory received approval from U.S. Food and Drug Administration (FDA).
The Republic of Ireland based company Shire was founded in 1986. Shire is focusing on R&D and production for rare diseases. The total revenue of Shire in 2016 was US4 11.6 billion and was generated US$ 1,516 million from immunology sales. The products of Shire are available in more than 100 countries and has about 23,900 employee strength.
All the major companies are investing money in R&D that will show positive impact on market growth.
Taste the market data and market information presented through more than 64 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Intravenous Immunoglobulin (IVIg) Market Research Report –Global Forecast to 2023.”
Considering the global scenario of the market, North America was holding largest market share in global IVIg market in 2016. While the European market, especially Western Europe is growing and second largest market for Global IVIg. Asia-Pacific will be fastest growing market for IVIg during the forecasted period. Middle East and Africa is expected to grow at steady pace during the forecast period.
Intravenous Immunoglobulin (IVIg) Market has been segmented on the basis of type which comprise Plaque psoriasis, Scalp psoriasis, Nail psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis, Erythrodermic psoriasis and others. Plaque psoriasis is most common type and about 80% of the cases are plaque psoriasis. On the basis of treatment type it segmented into Topical corticosteroids, Vitamin D analogues (Calcipotriene, Calcitriol), Anthralin, Topical retinoids (Retinol, Tretinoin (retinoic acid / retin-A /Steiva-A), Adapalene (Differin), Tazarotene), Calcineurin inhibitors (tacrolimus (Prograf), pimecrolimus (Elidel)), Salicylic acid, Coal tar, Moisturizers, and Others. Vitamin D analogs such as Calcipotriene and Calcitriol very helpful and helps to slow skin cell growth. Topical retinoids like are Retinol, Tretinoin (retinoic acid / retin-A /Steiva-A), Adapalene (Differin), Tazarotene are vitamin A derivatives that helps to reduce inflammation.
Access Report Details @ https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137
Table of Content
- Report Prologue
2.2 Scope of the Study
2.2.1 Research Objective
2.3 Market Structure
2.4. Market Segmentation
- Research Methodology
7.3 Multifocal Motor Neuropathy
7.4 Immunodeficiency diseases
7.4.1 X-linked agammaglobulinemia (XLA)
7.4.2 Common variable immunodeficiency (CVID)
7.2.4 Severe combined immunodeficiency
7.5 Primary Humoral Immunodeficiency
7.5.1 B cell (antibody) deficiencie
7.5.2 T cell deficiencies
7.5.3 Combination BT cell deficiencies
7.5.4 Defective phagocytes
7.5.5 Complement deficiencies
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Name: Akash Anand
Organization: Market Research Future
Address: Market Research Future Office No. 524/528,
Phone: +1 646 845 9312